KIT | KIT-Bibliothek | Impressum | Datenschutz

New medicines for neglected diseases. Summary

Gerlinger, Katrin


For many diseases that occur almost exclusively in poor countries, hardly any medicines are developed. Although medicines are developed for globally occurring diseases, they are usually too expensive for poor countries, as product development is (re)financed through sales at monopoly prices. For years, there has been a discussion on how to sustainably promote product development in this area and to what extent market mechanisms should be supplemented or even replaced. A closer look at and questioning of individual positions usually reveals a highly complex set of circumstances with local, national and global groups of actors and diverse interconnections of causes and effects.

Volltext §
DOI: 10.5445/IR/1000137284
Veröffentlicht am 22.10.2021
Cover der Publikation
Zugehörige Institution(en) am KIT Institut für Technikfolgenabschätzung und Systemanalyse (ITAS)
Publikationstyp Forschungsbericht/Preprint
Publikationsmonat/-jahr 02.2017
Sprache Englisch
Identifikator ISSN: 2364-2599
KITopen-ID: 1000137284
HGF-Programm 48.01.02 (POF III, LK 01) Knowledge society and knowledge policy
Verlag Büro für Technikfolgen-Abschätzung beim Deutschen Bundestag (TAB)
Umfang 24 S.
Serie TAB Working report ; 170
Externe Relationen Siehe auch
Schlagwörter Drug Research; Technology Assessment; Africa; Medicines; Drug supply; Developing countries; Europe; Research funding; Research policy; Intellectual property rights; Infectious disease; Innovation; Malaria; Emerging countries; Tropical disease; USA; Neglected disease; Public funding
Relationen in KITopen
KIT – Die Forschungsuniversität in der Helmholtz-Gemeinschaft
KITopen Landing Page